Psilocybin, the psychoactive compound found in so-called magic mushrooms, is gaining significant attention across the United States. Once considered a fringe substance, it is now entering mainstream discussions around mental health, wellness, and drug policy reform. A new national survey suggests that around 8 million Americans used psilocybin in 2024, highlighting how quickly public interest is growing.
This shift comes as several states and cities explore decriminalization measures, while researchers continue studying psilocybin as a possible treatment for depression and other mental health conditions.
Psilocybin is a naturally occurring psychedelic compound found in certain mushroom species. After consumption, the body converts it into psilocin, which affects serotonin receptors in the brain. This can alter perception, emotions, mood, and sense of time.
Users may experience:
Because of these powerful effects, psilocybin remains a controlled substance in many places, though legal attitudes are changing.
According to research led by the University of California San Diego School of Medicine and New York University, 2.8% of the U.S. population used psilocybin in the previous 12 months, which equals roughly 8 million people.
The findings were based on the 2024 National Survey on Drug Use and Health, one of the few major surveys that measures recent use rather than lifetime use.
This distinction matters because past surveys often grouped occasional past users with current users, making it harder to understand real trends.
Dr. Kevin Yang, a psychiatry resident at UC San Diego and lead author, noted that measuring past-year use gives a clearer picture of who is actively using psilocybin today.
The survey found that psilocybin use was highest among young adults aged 18 to 25. This age group was 1.4 times more likely to use the substance compared with adults in their late 30s or 40s.
Other trends included:
These patterns suggest psilocybin use may be part of broader experimentation with psychoactive substances.
One of the most notable findings was the relationship between psilocybin use and depression.
People who reported experiencing a major depressive episode in the previous year were significantly more likely to use psilocybin.
This may reflect a growing trend of self-medication, where individuals seek relief outside traditional healthcare systems. Many people have heard about promising clinical studies involving psilocybin-assisted therapy and may attempt similar experiences on their own.
However, experts caution that unsupervised use is very different from structured medical treatment.
Although clinical trials have shown potential benefits for treatment-resistant depression and major depressive disorder, those studies happen in carefully controlled environments.
In research settings, participants are typically:
At home, these protections are often absent.
Researchers warn that non-clinical use may lead to:
This is why medical experts stress caution despite growing enthusiasm.
The U.S. Food and Drug Administration has granted breakthrough therapy designation to psilocybin treatments for certain forms of depression. This status helps accelerate research into promising therapies.
While this does not mean psilocybin is fully approved as a mainstream medication, it does show serious scientific interest in its therapeutic potential.
If future studies continue to show positive results, psilocybin-assisted therapy could become more widely available under regulated medical supervision.
Researchers emphasized that healthcare providers should create open, non-judgmental conversations with patients about psilocybin use.
Many people may hesitate to discuss psychedelic use due to stigma or fear. But transparency can help doctors:
As public use increases, medical professionals may need better education and training around psychedelics.
The estimate of 8 million users shows psilocybin is no longer a niche issue. It is becoming a major public health, policy, and mental health topic.
Several trends are driving this growth:
The challenge ahead will be balancing scientific promise with public safety.
Psilocybin is rapidly moving into mainstream awareness, with millions of Americans now reporting recent use. While research into mental health benefits is encouraging, unsupervised use carries real risks.
As laws evolve and studies continue, education and responsible healthcare guidance will be essential. Psilocybin may become an important therapeutic tool in the future, but it is not risk-free, and it should not be viewed as a casual wellness trend.
This article is for informational and educational purposes only. It does not provide medical advice, diagnosis, or treatment. Statistics reflect population-level trends and may not apply to individual circumstances. Always consult a qualified healthcare professional before making health or medication decisions.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.